STX6 and adrenal cortex carcinoma: STX6 was a poor predictor of patient survival in ACC (p = 0.005; HR = 17.33), BRCA (p = 0.012; HR = 1.55), CESC (p = 0.019; HR = 1.78), HNSC (p = 0.022; HR = 1.39), KIRP (p < 0.001; HR = 5.18), LIHC (p = 0.001; HR = 1.82), MESO (p = 0.028; HR = 1.95), and OSCC (p = 0.038; HR = 1.44) among these malignancies (Figure S2B–D,H,I,K–M).